In short
Bidridistrogene Xeboparvovec, also known as SRP-9003, is an investigational gene therapy being studied for the treatment of Limb-Girdle Muscular Dystrophy Type 2E/R4 (LGMD2E/R4). This article discusses the ongoing clinical trials evaluating the safety and effectiveness of this promising therapy for patients with this rare genetic muscle disorder.
At a glance
- Study Type
- Phase 3, multinational, open-label gene delivery study
- Condition
- Limb-Girdle Muscular Dystrophy Type 2E/R4 (LGMD2E/R4)
- Intervention
- Bidridistrogene Xeboparvovec (SRP-9003)
- Primary Objective
- Evaluate β-sarcoglycan expression at Day 60 post-dose
- Key Secondary Objectives
- Assess physical function, safety, and disease progression
- Eligibility
- Patients ≥4 years old with confirmed LGMD2E/R4 mutations
- Study Duration
- 60 months (5 years) follow-up after treatment
- Key Assessments
- Muscle biopsies, functional tests, safety monitoring
What is BIDRIDISTROGENE XEBOPARVOVEC?
BIDRIDISTROGENE XEBOPARVOVEC, also known as SRP-9003, is an innovative gene therapy medication designed to treat a specific type of muscular dystrophy. This therapy is currently being studied in clinical trials to evaluate its safety and effectiveness in patients with Limb-Girdle Muscular Dystrophy Type 2E/R4 (LGMD2E/R4).
The medication is classified as an advanced therapy medicinal product, specifically a gene therapy. It uses a modified virus called adeno-associated virus serotype rh74 (AAVrh74) to deliver a healthy copy of the β-sarcoglycan gene to muscle cells.
Target Condition: Limb-Girdle Muscular Dystrophy Type 2E/R4
BIDRIDISTROGENE XEBOPARVOVEC is designed to treat Limb-Girdle Muscular Dystrophy Type 2E/R4 (LGMD2E/R4), also known as β-sarcoglycanopathy. This is a rare genetic disorder that causes progressive muscle weakness, primarily affecting the shoulders, upper arms, pelvic area, and thighs. The condition is caused by mutations in the gene that produces a protein called β-sarcoglycan, which is important for maintaining muscle fiber strength and stability.
How Does BIDRIDISTROGENE XEBOPARVOVEC Work?
BIDRIDISTROGENE XEBOPARVOVEC works by introducing a functional copy of the β-sarcoglycan gene into the patient's muscle cells. Here's a simplified explanation of the process:
- The medication contains a modified virus (AAVrh74) that carries a healthy copy of the β-sarcoglycan gene.
- This virus is engineered to be harmless and serves only as a delivery vehicle for the gene.
- The medication is administered to the patient through intravenous infusion (directly into the bloodstream).
- The virus travels through the bloodstream and enters muscle cells.
- Once inside the cells, the healthy gene is released, allowing the cells to produce the β-sarcoglycan protein.
- The presence of this protein helps strengthen and stabilize muscle fibers, potentially slowing or halting the progression of the disease.
Current Clinical Trial
BIDRIDISTROGENE XEBOPARVOVEC is currently being studied in a Phase 3 clinical trial. This trial is designed to evaluate the safety and efficacy of the treatment in patients with LGMD2E/R4. The study is multinational and open-label, meaning that both the researchers and participants know which treatment is being administered.
The trial includes two groups of participants:
- Cohort 1: Ambulatory subjects (able to walk without assistance)
- Cohort 2: Non-ambulatory subjects (unable to walk or requiring significant assistance)
Who Can Participate in the Trial?
The trial has specific criteria for who can participate. Some key eligibility requirements include:
- Age 4 years or older
- Confirmed genetic diagnosis of LGMD2E/R4
- For Cohort 1 (ambulatory): Able to walk without assistance and complete certain physical tests
- For Cohort 2 (non-ambulatory): Unable to walk or requiring significant assistance, but able to perform certain upper limb functions
- No recent infections or major surgeries
- No previous gene therapy treatments
- No significant heart or lung problems
What Are the Trial Objectives?
The main goals of the clinical trial include:
- Evaluating the effect of SRP-9003 on β-sarcoglycan expression in muscle tissue
- Assessing improvements in physical function over time
- Monitoring the safety of the treatment
- Measuring changes in muscle enzyme levels (creatine kinase)
- Tracking disease milestones, such as loss of ambulation (ability to walk)
Safety Considerations
As with any experimental treatment, there are potential risks and safety considerations. The clinical trial closely monitors participants for:
- Side effects related to the treatment
- Immune reactions to the viral vector
- Changes in heart and lung function
- Abnormal laboratory values
To help manage potential immune reactions, participants receive a course of glucocorticoids (a type of steroid) starting shortly before the treatment.